Skip to content

US · REVB · BIOTECHNOLOGY

Revelation Biosciences, Inc. (REVB) intrinsic value and stock valuation

$3.50as of 2026-11-21 · Mkt cap 4.49M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Revelation Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values REVB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from REVB’s statements →

Revelation Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92122 revbiosciences.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-8.91M
20192025
Free cash flow
-$-8.27M
20192025
Total equity
$8.86M+21% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-9.07M-$-7.98M-$-8.66M-$-10.86M-$-11.95M
Net income-$-8.91M-$-15.04M-$-120K-$-10.83M-$-11.99M
EPSd-$-14.37M-$-88.47M-$-12M——
Operating cash flow-$-8.27M-$-18.32M-$-7.29M-$-11.22M-$-11.09M
Capital expenditure$0.00-$-20K$0.00$0.00-$-130K
Free cash flow-$-8.27M-$-18.34M-$-7.29M-$-11.22M-$-11.22M
Total assets$11.6M$6.62M$12.2M$5.5M$2.04M
Total debt$750K$0.00$0.00$0.00$20K
Net debt-$-9.95M-$-6.5M-$-11.99M-$-5.25M-$-1.26M
Total equity$8.86M$4.71M$6.65M$1.05M-$-100K
Cash and short-term investments$10.7M$6.5M$12M$5.25M$1.27M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$30K$30K$30K$40K$70K
Gross profit-$-30K-$-30K-$-30K-$-40K-$-70K
Research and development expenses$4.06M$3.55M$4.15M$5.38M$6.91M
Selling, general and administrative expenses$5.01M$4.43M$4.51M$5.49M$5.04M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$9.07M$7.98M$8.66M$10.9M$12M
Cost and expenses$9.07M$7.98M$8.66M$10.9M$12M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$40K
Depreciation and amortization$30K$30K$30K$30K$20K
Ebitda-$-9.04M-$-7.95M-$-8.63M-$-10.84M-$-11.93M
Operating income-$-9.07M-$-7.98M-$-8.66M-$-10.86M-$-11.95M
Total other income/expenses, net$160K-$-7.06M$8.54M$30K-$-40K
Income before tax-$-8.91M-$-15.04M-$-120K-$-10.83M-$-11.99M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-8.91M-$-15.04M-$-120K-$-10.83M-$-11.99M
Weighted average shares outstanding$620K$170K$10K$0.00$0.00
Weighted average diluted shares outstanding$620K$170K$10K$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$10.7M$6.5M$12M$5.25M$1.27M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$10.8M$6.57M$12.2M$5.41M$1.91M
Property, plant and equipment, net$740K$60K$70K$90K$130K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$770K$60K$70K$90K$130K
Total assets$11.6M$6.62M$12.2M$5.5M$2.04M
Accounts payable$580K$780K$1.36M$550K$600K
Short-term debt$20K$0.00$0.00$0.00$30K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2M$1.91M$5.56M$4.45M$2.14M
Long-term debt$720K$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$720K$0.00$0.00$0.00$0.00
Capital lease obligations$720K$0.00$0.00$0.00$20K
Total liabilities$2.72M$1.91M$5.56M$4.45M$2.14M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-49.42M-$-40.51M-$-25.47M-$-25.35M-$-14.52M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$8.86M$4.71M$6.65M$1.05M-$-100K
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$750K$0.00$0.00$0.00$20K
Net debt-$-9.95M-$-6.5M-$-11.99M-$-5.25M-$-1.26M
Cash flow statement
20252024202320222021
Net income-$-8.91M-$-15.04M-$-120K-$-10.83M-$-11.99M
Depreciation and amortization$30K$30K$30K$30K$20K
Stock-based compensation$600K$170K$160K$300K$470K
Change in working capital-$-10K-$-3.42M$980K-$-730K$360K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-210K-$-580K$750K-$-670K-$-270K
Net cash provided by operating activities-$-8.27M-$-18.32M-$-7.29M-$-11.22M-$-11.09M
Investments in property, plant and equipment$0.00-$-20K$0.00$0.00-$-130K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-20K$0.00$0.00-$-130K
Common stock issued$12.5M$12.9M$14M$4.45M$600K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.5M$12.9M$14M$15.2M$8M
Net change in cash$4.2M-$-5.49M$6.74M$3.98M-$-3.22M
Cash at end of period$10.7M$6.5M$12M$5.25M$1.27M
Operating cash flow-$-8.27M-$-18.32M-$-7.29M-$-11.22M-$-11.09M
Capital expenditure$0.00-$-20K$0.00$0.00-$-130K
Free cash flow-$-8.27M-$-18.34M-$-7.29M-$-11.22M-$-11.22M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Revelation Biosciences, Inc.

        Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

        CEO
        James Rolke
        Employees
        8
        Beta
        -0.17

        Explore

        Frequently asked questions

        What is the intrinsic value of Revelation Biosciences, Inc. (REVB)?

        InvestorsCraft does not currently publish an intrinsic value for REVB. How the IC value is calculated.

        Is REVB undervalued?

        InvestorsCraft does not publish an undervaluation signal for REVB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.